Intellia Therapeutics (NTLA) Income towards Parent Company (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Income towards Parent Company data on file, last reported at -$95.3 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$95.3 million, up 15.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$394.9 million (up 20.59% YoY), and the FY2025 annual result was -$411.8 million, up 15.35% from the prior year.
• Income towards Parent Company declined to -$95.3 million in Q1 2026 per NTLA's latest filing, from -$92.2 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$92.2 million in Q4 2025 and troughed at -$143.7 million in Q1 2022.
• A 5-year average of -$112.3 million and a median of -$104.8 million in 2025 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company sank 211.02% in 2022, then surged 30.43% in 2023.
• A 5-year view of Income towards Parent Company shows it stood at -$104.7 million in 2022, then fell by 21.67% to -$127.4 million in 2023, then climbed by 1.27% to -$125.8 million in 2024, then gained by 26.69% to -$92.2 million in 2025, then retreated by 3.35% to -$95.3 million in 2026.
• Business Quant data shows NTLA's Income towards Parent Company at -$95.3 million in Q1 2026, -$92.2 million in Q4 2025, and -$104.8 million in Q3 2025.